key: cord-1019074-wpsot2yq authors: Kijima, Yu; Shimizu, Tomokazu; Shinya, Kato; Kano, Kana; Horiuchi, Toshihide; Nozaki, Taiji; Omoto, Kazuya; Inui, Masashi; Toma, Hiroshi; Iida, Shoichi; Takagi, Toshio title: A Case Report of COVID-19 infection after kidney transplantation treated with casirivimab-imdevimab and mycophenolate mofetil changed to everolimus date: 2021-12-31 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.12.018 sha: 8ebee28fee78fec0e77f5d4fc4a17cf7156bfb83 doc_id: 1019074 cord_uid: wpsot2yq Background Casirivimab-imdevimab is a cocktail of two monoclonal antibodies designed to prevent infection by SARS-CoV-2, the virus that causes COVID-19. Casirivimab-imdevimab has been approved in Japan for treating mild to moderate coronavirus disease (COVID-19); however, to the best of our knowledge, there are no reports of its use after kidney transplantation from a live donor. Everolimus, antineoplastic chemotherapy drug, is expected to be effective in inhibiting the spread of SARS-CoV-2 and preventing its replication, which may facilitate treatment. Here, we report a case of COVID-19 infection following kidney transplantation, that was initially treated with casirivimab-imdevimab and mycophenolate mofetil, but was later changed to everolimus. Case report A 47-year-old man underwent living donor kidney transplantation from his mother in 2017. Immunosuppression therapy was underway through the administration of tacrolimus, mycophenolate mofetil, and methylprednisolone. In early September 2021, he was diagnosed with COVID-19 and was hospitalized on Day 3 (Table 1). On hospitalization, mycophenolate mofetil was discontinued and casirivimab-imdevimab and heparin were started. The patient was started on everolimus on Day 5. The clinical course was successful without rejection (Fig. 1). There was no exacerbation of COVID-19; the patient's serum creatinine levels and renal function had otherwise remained stable. Conclusion We could safely treat a patient with casirivimab-imdevimab after kidney transplantation. It is suggested that casirivimab-imdevimab can prevent COVID-19 from becoming severe and can be administered without worsening renal function. In addition, everolimus may have inhibited the spread of the virus and prevented it from replicating. Casirivimab-imdevimab has been approved in Japan for treating mild to moderate coronavirus disease (COVID-19); however, to the best of our knowledge, there are no reports of its use after living kidney transplantation. Everolimus , antineoplastic chemotherapy drug, is expected to be effective in inhibiting the spread of SARS-CoV-2 and preventing its replication, which may facilitate treatment. Here, we report a case of COVID-19 infection after kidney transplantation; the patient was initially treated with casirivimab-imdevimab and mycophenolate mofetil, but the treatment was later changed to everolimus. A 47-year-old man with end-stage renal disease caused by chronic glomerulonephritis, received a living related kidney transplant from his mother in January 2017. The patient had a history of hypertension, peritoneal dialysis-related peritonitis, umbilical hernia repair, and sleep apnea syndrome. After surgery, he was on immunosuppressive treatment comprising tacrolimus, mycophenolate mofetil, and methylprednisolone. On September 6th, 2021, the patient presented with fever, cough, sputum, and a sore throat. Computed tomography (CT) showed no pneumonia. He tested positive for COVID-19 and was hospitalized on Day 3. Physical examination revealed a body temperature, 38.6 °C; blood pressure, 120/74 mm Hg; pulse, 89 beats/min; and blood oxygen saturation (SPO 2 ), 97% (in room air). Laboratory data showed an increased C-reactive protein (CRP) level (1.66 mg/dL) and serum creatinine level (1.45 mg/dL) ( Table 1) . On hospitalization, mycophenolate mofetil was discontinued and casirivimab-imdevimab and heparin were started. On Day 5, the patient started on everolimus. The clinical course was successful without any evidence of organ rejection (Fig. 1 ). There was no exacerbation of COVID-19; the patient's serum creatinine levels and renal function had otherwise remained stable. The patient was discharged on the 11 th day after hospitalization. We present a case of COVID-19 treated with antibody cocktail therapy after kidney who were treated with casirivimab-imdevimab had worsening symptoms or required hospitalization due to COVID-19 [2] . Additionally, a retrospective study in USA reported 707 confirmed COVID-19 cases treated with neutralizing monoclonal antibodies (bamlanivimab or casirivimab and imdevimab) [3] . In this report, the use of neutralizing monoclonal antibodies reduced the need for hospitalization in mild and moderate cases of COVID-19 [3] . In our case, there was no exacerbation during hospitalization, and no need to extend hospital stay. Currently, casirivimab-imdevimab (suitable for mild to moderate disease I), remdesivir, dexamethasone, and baricitinib (suitable for moderate disease II and above) have been approved for use in Japan. Heparin is recommended in patients with moderate disease II and above [4] . We selected casirivimab-imdevimab and heparin for our patient with COVID-19 pneumonia. COVID-19 after living donor kidney transplantation has a higher mortality rate (28%) than in the general population [5] . Treatment with mycophenolic acid and everolimus has been reportedly reduced or discontinued (68%), and that with calcineurin inhibitors has been discontinued (32%) [6] . However, we subsequently changed the treatment to everolimus. In SARS-CoV2 infection, everolimus is also expected to be effective in preventing replication by inhibiting the spread of the virus [7] . Also, mTOR inhibitors such as everolimus suppress the early production of B-cells and decrease the populations of antigen-specific memory B-cells [8] . Therefore, COVID-19 patients treated with mTOR inhibitors would be expected to have reduced cross-reactive antibody production, resulting in reduced antibody-dependent potentiation [9] . Everolimus has been reported to reduce the risk of COVID-19-associated death in kidney transplant recipients [10] . Everolimus may also have modulated the immune response in SARS-CoV2 infection by acting as a key molecule in immune regulation. We could safely treat a COVID-19 patient with casirivimab-imdevimab after kidney transplantation. It is suggested that casirivimab-imdevimab can prevent COVID-19 from becoming severe and can be administered without worsening renal function. In addition, everolimus may have inhibited the spread of the virus and prevented it from replicating. T-Bil, total bilirubin; WBC, white blood count. Food and Drug Administration, Casirivimab and Imdevimab EUA Letter of Authorization Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: An early experience Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus Disease 2019 (COVID-19): A real-world experience Guide to the Treatment of COVID-19 Version 5.3 Covid-19 and kidney transplantation COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium An open question: Is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy? Rapamycin: Drug Repurposing in SARS-CoV-2 Infection mTOR inhibition: a double-edged sword in patients with COVID-19? Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients The authors would like to thank Editage (www.editage.jp) for English language editing.